ClinicalTrials.gg
Status unknownNCT05550545ResQFamilyUpdated Oct 18, 2022

Infant RSV Infections and Health-related Quality of Life of Families

An observational study in RSV Infection, Quality of Life and Infant ALL, sponsored by Global Foundation for the Care of Newborn Infants. Status unknown at 1 site in Germany. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2022-10-18.

Sponsored by Global Foundation for the Care of Newborn Infants · Observational

How we know

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
120
Ages
0 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Respiratory Syncytial Virus Infections with a site in Germany — none open to participants now, 3 under way, 2 of them phase 3. Respiratory Syncytial Virus Infections · Germany.

Started
2022
with 1 other
Observational
3 of 25
none open now
Registered
20th of 25
by date
Lead sponsor
1 of 25
Global Foundation for the Care of Newborn Infants

Among the 25 studies in Respiratory Syncytial Virus Infections with a site in Germany, this one is one of 2 that started in 2022, is one of 3 observational ones, and was the 20th registered.

Respiratory Syncytial Virus Infections

307 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 50 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

None of the 25 studies in Respiratory Syncytial Virus Infections with a site in Germany is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 0 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies in Respiratory Syncytial Virus Infections with a site in Germany as a file.
02

Study summary

Until today, there is only little information available on how severe RSV infection leading to hospitalisation of the infant impacts the quality of life of affected families. For the ResQ Family project, an online questionnaire will be used to survey parents or caregivers of children up to 24 months currently or recently hospitalised (length of hospital stay of at least 12 hours and hospital admission no longer than 4 weeks ago) due to RSV infection.

The aim of the ResQ Family project is to find out how infant RSV hospitalisation impacts the quality of life of affected children and their families. The goal is further to provide scientific evidence on the burden of RSV and raise awareness among all relevant stakeholders including healthcare professionals and patient representatives, decision-makers and the general public. The project will run until June 2024. Data collection will take place during the RSV season from fall 2022 to spring 2023 in four European countries: France, Germany, Italy, and Sweden.

Read the detailed description

Respiratory Syncytial Virus (RSV) is a very contagious virus and the most common cause of lower respiratory tract infections such as bronchiolitis and pneumonia in infants. By the age of two years, nearly all infants will be infected with RSV at least once. Globally, it is a leading cause of hospitalisations among young infants with approximately 33 million cases of acute lower respiratory infections causing more than three million hospitalisations each year in children younger than 5 years. While most RSV cases are mild, one can't predict which infants could get seriously ill and end up in hospital. This is because the course of the disease is unpredictable.

When the RSV infection of the child is severe and associated with hospitalisation, it may lead to intensive care unit admissions with use of supportive care such as mechanical ventilation. It may further result in long-term complications such as recurrent wheezing, reduced pulmonary function and asthma. Moreover, RSV-related hospitalisations can be associated with a significant burden on the entire family, causing considerable stress and increased loss of work productivity. Currently, there is a lack of adequate information on how severe RSV infection leading to hospitalisation of infants (\< 2 years) impacts the quality of life of affected families.

To close this knowledge gap, the ResQ Family research project was initiated: ResQ Family: Impact of Respiratory Syncytial Virus (RSV) hospitalisation on Quality of life of Families - a multi-country study. The project runs from December 2021 until June 2024 and covers four European countries: France, Germany, Italy and Sweden. Data will be collected between autumn 2022 and spring 2023, corresponding to a typical RSV season duration in temperate countries in the northern hemisphere.

The aim of the ResQ Family study is to find out how infant RSV hospitalisation impacts the quality of life of affected children and their families. The goal is further to provide scientific evidence on the burden of RSV and raise awareness among all relevant stakeholders including healthcare professionals and patient representatives, decision-makers and the general public.

An online questionnaire will be used to ask parents and caregivers of children experiencing (or having recently experienced) hospitalisation due to RSV infection to share their experiences and a follow-up will take place after six weeks. The study focuses on children up to 24 months with a hospital stay due to RSV infection of at least 12 hours in total. The hospital admission should not be longer than 4 weeks ago.

Experienced researchers and health care professionals renowned in the field of RSV as well as parent/patient representatives support the project as part of an external scientific advisory board and a project expert group.

EFCNI received a research grant from Sanofi in support of this independent study.

03

Conditions studied

  • RSV Infection
  • Quality of Life
  • Infant ALL
  • Caregiver Burden
  • Family

Keywords

  • RSV
  • Respiratory syncytial virus
  • quality of life
  • health literacy
  • infants
  • children
  • caregiver burden
04

Who can participate

Ages eligible
0 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Parents or caregivers of children younger than 24 months of age with a hospitalisation for at least 12 hours due to RSV infection in Germany, Sweden, Italy or France.

Eligibility criteria

Inclusion Criteria:

  • Parents or caregivers of children younger than 24 months of age with a hospitalisation for at least 12 hours due to RSV infection
  • Living in Germany, Sweden, Italy or France
  • The diagnosis can either be confirmed by a test such as ELISA/IFT/PCR from nasal secretion, sputum or throat swab or by a doctor based on specific symptoms typically during the RSV season
  • They can be reached during or after hospitalisation, ideally right after the discharge from hospital but at least within four weeks after hospital admission
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • Parents/caregivers of RSV-infected infants

    Other: cohort study

Interventions

  • Othercohort study

    Please note that this is an observational study; not applicable

06

What researchers measure

Primary outcomes

  1. Health-related quality of life of parents/caregivers and family functioning

    The 36-item version of the Pediatric Quality of Life Inventory Family Impact Module (PedsQLTM FIM) was used to assess the quality of life of parents/caregiver when the child was infected and hospitalized for RSV. It composes of six scales measuring parent self-reported functioning: 1) Physical functioning (6 items), 2) Emotional functioning (5 items), 3) Social functioning (4 items), 4) Cognitive functioning (5 items), 5) Communication (3 items), 6) Worry (5 items), and in addition two scales measuring parent-reported family functioning: 7) Daily activities (3 items) and 8) Family relationships (5 items). Each of the items have five Likert response options: 0 = never a problem, 1 = almost never, 2 = sometimes, 3 = often, 4= almost always. Items are reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), so that higher scores indicate better functioning (less negative impact).

    Time frame: Baseline (Day 0)

  2. Health-related quality of life of parents/caregivers and family functioning

    The 36-item version of the Pediatric Quality of Life Inventory Family Impact Module (PedsQLTM FIM) was used to assess the quality of life of parents/caregiver when the child was infected and hospitalized for RSV. It composes of six scales measuring parent self-reported functioning: 1) Physical functioning (6 items), 2) Emotional functioning (5 items), 3) Social functioning (4 items), 4) Cognitive functioning (5 items), 5) Communication (3 items), 6) Worry (5 items), and in addition two scales measuring parent-reported family functioning: 7) Daily activities (3 items) and 8) Family relationships (5 items). Each of the items have five Likert response options: 0 = never a problem, 1 = almost never, 2 = sometimes, 3 = often, 4= almost always. Items are reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), so that higher scores indicate better functioning (less negative impact).

    Time frame: 6 weeks follow-up (Week 6)

Secondary outcomes

  1. Socio-demographics

    Parental self-report - self-designed questions: socio-demographics (parents/caregiver), risk factors (smoking, allergic diseases), place of living, birth weight (child, categories and in grams), RSV prophylaxis, breastfeeding, day-care attendance

    Time frame: Baseline (Day 0)

  2. Child's co-morbidities

    Parental self-report - self-designed questions: pre-existing health-conditions before or apart from the current recent hospitalisation due to RSV

    Time frame: Baseline (Day 0)

  3. Child's symptoms during RSV infection and hospitalisation

    Parental self-report - self-designed questions: RSV diagnose (child), duration of hospitalisation (in days), supportive care measure in hospital, feelings (parents) in relation to the hospitalisation of the child (categories), presence with the child receiving special/intensive care, duration of symptoms (up to 7 days and more), child's behaviour (categories), worry of parents/caregiver about symptoms (categories)

    Time frame: Baseline (Day 0)

  4. Child's symptoms after RSV infection and hospitalisation

    Parental self-report - self-designed questions: Duration of symptoms (in days), child's behaviour, worry of parents/caregiver about symptoms (categories)

    Time frame: 6 weeks follow-up (Week 6)

  5. Other

    Parental self-report - self-designed questions: Health literacy, support structures, loss of work productivity (in hours), subjective assessment of parental health status (categories: 1=very bad to 10 = excellent), overall impact of the entire RSV episode (open question)

    Time frame: Baseline (Day 0)

  6. Other

    Parental self-report - self-designed questions: Loss of work productivity (in hours), subjective assessment of parental health status (categories: 1=very bad to 10 = excellent), overall impact of the entire RSV episode (open question)

    Time frame: 6 weeks follow-up (Week 6)

07

Study locations

1 of 1 sites recruiting
  • EFCNI
    Munich, Bavaria 81379, Germany
    Recruiting
    • Christina Tischer, PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for May 2023, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2022
First posted
Sep 22, 2022
StartActual
Sep 29, 2022
Primary completionEst.
May 2023
CompletionEst.
Jun 2024
Last update
Oct 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05550545
Lead sponsor
Global Foundation for the Care of Newborn Infants
Collaborators
Respiratory Syncytial Virus Foundation (ReSViNET), European Society for Paediatric Research (ESPR), Union of European Neonatal and Perinatal Societies (UENPS)
Responsible party
Johanna Kostenzer (Head of Scientific Affairs, Global Foundation for the Care of Newborn Infants) — Principal investigator
First posted
Sep 22, 2022
Start date
Sep 29, 2022
Primary completion
May 2023 (estimated)
Completion
Jun 2024 (estimated)
Last update
Oct 18, 2022

Study contacts

Christina Tischer, PhD
Contact
research@efcni.org
+49 (0)89 / 89083260
Christina Tischer, PhD
Contact
christina.tischer@efcni.org
+49 (0)89 / 89083260
Johanna Kostenzer, PhD
principal investigator · Global Foundation for the Care of Newborn Infants

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion